Identification

Name
Pamidronate
Accession Number
DB00282  (APRD01161)
Type
Small Molecule
Groups
Approved
Description

Pamidronic acid (INN) or pamidronate disodium (USAN), marketed as pamidronate disodium pentahydrate under the brand name Aredia, is a bisphosphonate. [Wikipedia]

Structure
Thumb
Synonyms
  • Acide pamidronique
  • Acido pamidronico
  • Acidum pamidronicum
  • Pamidronic acid
  • Ribodroat
Product Ingredients
IngredientUNIICASInChI Key
Pamidronate DisodiumC7S8VWP5DH109552-15-0CEYUIFJWVHOCPP-UHFFFAOYSA-L
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ArediaPowder, for solution60 mgIntravenousNovartis1994-12-312001-07-30Canada
Aredia 30mgPowder, for solution30 mgIntravenousNovartis1994-12-312016-02-23Canada
Aredia 90mgPowder, for solution90 mgIntravenousNovartis1994-12-312016-02-23Canada
Aredia Liq Inj 3mg/mlLiquid3 mgIntravenousGeigy Pharmaceuticals, Ciba Geigy Canada Ltd.1992-12-311996-09-09Canada
Pamidronate Disodium for InjectionSolution3 mgIntravenousSandoz Canada Incorporated2006-07-12Not applicableCanada
Pamidronate Disodium for InjectionPowder, for solution30 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Pamidronate Disodium for InjectionSolution6 mgIntravenousPfizer2001-08-31Not applicableCanada
Pamidronate Disodium for InjectionSolution9 mgIntravenousFresenius Kabi2004-03-01Not applicableCanada
Pamidronate Disodium for InjectionPowder, for solution90 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Pamidronate Disodium for InjectionSolution3 mgIntravenousFresenius Kabi2004-03-01Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pamidronate DisodiumInjection, powder, lyophilized, for solution3 mg/mLIntravenousAreva Pharmaceuticals,Inc.2013-08-06Not applicableUs
Pamidronate DisodiumInjection, solution9 mg/mLIntravenousTeva Parenteral Medicines, Inc.2002-04-01Not applicableUs
Pamidronate DisodiumInjection3 mg/mLIntravenousSagent Pharmaceuticals2010-01-152016-10-21Us
Pamidronate DisodiumInjection, solution6 mg/mLIntravenousHospira, Inc.2002-06-27Not applicableUs
Pamidronate DisodiumInjection, solution9 mg/mLIntravenousAPP Pharmaceuticals, Inc.2002-05-19Not applicableUs
Pamidronate DisodiumInjection, solution9 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2011-05-10Not applicableUs
Pamidronate DisodiumInjection, solution3 mg/mLIntravenousHospira, Inc.2002-06-27Not applicableUs
Pamidronate DisodiumInjection9 mg/mLIntravenousMylan Institutional2008-11-01Not applicableUs
Pamidronate DisodiumInjection, solution9 mg/mLIntravenousAmerican Regent2010-08-09Not applicableUs
Pamidronate DisodiumInjection9 mg/mLIntravenousSagent Pharmaceuticals2010-01-152016-10-21Us
International/Other Brands
Aminomux / Pamimed
Categories
UNII
OYY3447OMC
CAS number
40391-99-9
Weight
Average: 235.0695
Monoisotopic: 235.001074735
Chemical Formula
C3H11NO7P2
InChI Key
WRUUGTRCQOWXEG-UHFFFAOYSA-N
InChI
InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)
IUPAC Name
(3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid
SMILES
NCCC(O)(P(O)(O)=O)P(O)(O)=O

Pharmacology

Indication

For the treatment of moderate or severe hypercalcemia associated with malignancy

Structured Indications
Pharmacodynamics

Pamidronate is in a class of drugs called bisphosphonates. Pamidronate reduces breakdown of the bones. Pamidronate is used in the treatment of Paget's disease of bone; to reduce high levels of calcium in the blood associated with malignancy (cancer); and to reduce the breakdown of bone due to metastases of breast cancer or multiple myeloma.

Mechanism of action

The mechanism of action of pamidronate is inhibition of bone resorption. Pamidronate adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption. Pamidronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

TargetActionsOrganism
AFarnesyl pyrophosphate synthase
inhibitor
Human
AHydroxylapatite
antagonist
Human
Absorption

Plasma concentration rises rapidly upon IV administration.

Volume of distribution
Not Available
Protein binding

Approximately 54% to human serum proteins.

Metabolism

Pamidronate is not metabolized and is exclusively eliminated by renal excretion

Route of elimination

Pamidronate is not metabolized and is exclusively eliminated by renal excretion.

Half life

The mean ± SD elimination half-life is 28 ± 7 hours

Clearance
  • 107 +/- 50 mlL/min
Toxicity

Side effects include an allergic reaction, kidney problems, seizures, low levels of calcium, magnesium, or phosphorus in the blood

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Pamidronate Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Pamidronate.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Pamidronate.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pamidronate.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Pamidronate.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pamidronate.Approved, Vet Approved
AclarubicinAclarubicin may increase the hypocalcemic activities of Pamidronate.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Pamidronate.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Pamidronate.Approved, Withdrawn
AlgeldrateThe serum concentration of Pamidronate can be decreased when it is combined with Algeldrate.Approved, Experimental
AlmagateThe serum concentration of Pamidronate can be decreased when it is combined with Almagate.Experimental
AlmasilateThe serum concentration of Pamidronate can be decreased when it is combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Pamidronate.Experimental
AloglutamolThe serum concentration of Pamidronate can be decreased when it is combined with Aloglutamol.Experimental
AluminiumThe serum concentration of Pamidronate can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Pamidronate can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Pamidronate can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Pamidronate can be decreased when it is combined with Aluminum hydroxide.Approved
AmikacinAmikacin may increase the hypocalcemic activities of Pamidronate.Approved, Vet Approved
AmrubicinAmrubicin may increase the hypocalcemic activities of Pamidronate.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Pamidronate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Pamidronate.Investigational
annamycinannamycin may increase the hypocalcemic activities of Pamidronate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Pamidronate.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Pamidronate.Investigational
ApramycinApramycin may increase the hypocalcemic activities of Pamidronate.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Pamidronate.Approved, Investigational
ArbekacinArbekacin may increase the hypocalcemic activities of Pamidronate.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Pamidronate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pamidronate.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Pamidronate.Approved, Investigational
BekanamycinBekanamycin may increase the hypocalcemic activities of Pamidronate.Experimental
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Pamidronate.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Pamidronate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pamidronate.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Pamidronate.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Pamidronate.Approved, Investigational
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Pamidronate.Experimental
Bismuth SubcitrateThe serum concentration of Pamidronate can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Pamidronate can be decreased when it is combined with Bismuth subnitrate.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pamidronate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Pamidronate.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Pamidronate.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Pamidronate.Experimental
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pamidronate.Approved
Calcium AcetateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium Acetate.Approved
Calcium CarbonateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium Carbonate.Approved
Calcium ChlorideThe serum concentration of Pamidronate can be decreased when it is combined with Calcium Chloride.Approved
Calcium CitrateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium Citrate.Approved
Calcium glubionateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium glubionate.Approved
Calcium GluceptateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium Gluceptate.Approved
Calcium gluconateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium lactate gluconate.Experimental
Calcium laevulateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium laevulate.Experimental
Calcium pangamateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium pangamate.Experimental
Calcium PhosphateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium Phosphate.Approved
Calcium silicateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium silicate.Experimental
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Pamidronate.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Pamidronate.Approved, Vet Approved, Withdrawn
CaseinThe serum concentration of Pamidronate can be decreased when it is combined with Casein.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pamidronate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Pamidronate.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Pamidronate.Approved, Vet Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pamidronate.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Pamidronate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Pamidronate.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pamidronate.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Pamidronate.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Pamidronate.Investigational
DaunorubicinDaunorubicin may increase the hypocalcemic activities of Pamidronate.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Pamidronate is combined with Deferasirox.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pamidronate.Approved
DexlansoprazoleThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Dexlansoprazole.Approved
DexrabeprazoleThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Dexrabeprazole.Experimental
DibekacinDibekacin may increase the hypocalcemic activities of Pamidronate.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pamidronate.Approved, Vet Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Pamidronate.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pamidronate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pamidronate.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Pamidronate.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pamidronate.Approved
DihydrostreptomycinDihydrostreptomycin may increase the hypocalcemic activities of Pamidronate.Investigational, Vet Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pamidronate.Approved, Investigational
DoxorubicinDoxorubicin may increase the hypocalcemic activities of Pamidronate.Approved, Investigational
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Pamidronate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Pamidronate.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Pamidronate.Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Pamidronate.Approved
EpirubicinEpirubicin may increase the hypocalcemic activities of Pamidronate.Approved
EsomeprazoleThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Esomeprazole.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Pamidronate.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Pamidronate.Experimental
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Pamidronate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Pamidronate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Pamidronate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Pamidronate.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Pamidronate.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Pamidronate.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Pamidronate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Pamidronate.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Pamidronate.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Pamidronate.Experimental
Ferric CitrateThe serum concentration of Pamidronate can be decreased when it is combined with Ferric Citrate.Approved, Investigational
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Pamidronate.Experimental
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Pamidronate.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Pamidronate.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Pamidronate.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pamidronate.Approved, Investigational
FramycetinFramycetin may increase the hypocalcemic activities of Pamidronate.Approved
GeneticinGeneticin may increase the hypocalcemic activities of Pamidronate.Experimental
GentamicinGentamicin may increase the hypocalcemic activities of Pamidronate.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the hypocalcemic activities of Pamidronate.Experimental
GitoformateGitoformate may decrease the cardiotoxic activities of Pamidronate.Experimental
GPX-150GPX-150 may increase the hypocalcemic activities of Pamidronate.Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Pamidronate.Experimental
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Pamidronate.Investigational
HydrotalciteThe serum concentration of Pamidronate can be decreased when it is combined with Hydrotalcite.Experimental, Investigational
Hygromycin BHygromycin B may increase the hypocalcemic activities of Pamidronate.Vet Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pamidronate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Pamidronate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Pamidronate.Approved
IdarubicinIdarubicin may increase the hypocalcemic activities of Pamidronate.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Pamidronate.Experimental
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Pamidronate.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pamidronate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Pamidronate.Withdrawn
INNO-206INNO-206 may increase the hypocalcemic activities of Pamidronate.Investigational
Iron saccharateThe serum concentration of Pamidronate can be decreased when it is combined with Iron saccharate.Approved
IsepamicinIsepamicin may increase the hypocalcemic activities of Pamidronate.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Pamidronate.Withdrawn
KanamycinKanamycin may increase the hypocalcemic activities of Pamidronate.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Pamidronate.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Pamidronate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pamidronate.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Pamidronate.Experimental
LansoprazoleThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Lansoprazole.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Pamidronate.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pamidronate.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Pamidronate.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Pamidronate.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Pamidronate.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Pamidronate.Approved, Investigational
Magnesium HydroxideThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium salicylateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium SulfateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium Trisilicate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pamidronate.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pamidronate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pamidronate.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pamidronate.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Pamidronate.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Pamidronate.Investigational, Withdrawn
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Pamidronate.Experimental
MetrizamideMetrizamide may increase the hypocalcemic activities of Pamidronate.Approved
MicronomicinMicronomicin may increase the hypocalcemic activities of Pamidronate.Experimental
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pamidronate.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Pamidronate.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pamidronate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pamidronate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Pamidronate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Pamidronate.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Pamidronate.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Pamidronate.Approved, Vet Approved
NeamineNeamine may increase the hypocalcemic activities of Pamidronate.Experimental
NeomycinNeomycin may increase the hypocalcemic activities of Pamidronate.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Pamidronate.Approved
NetilmicinNetilmicin may increase the hypocalcemic activities of Pamidronate.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Pamidronate.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pamidronate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pamidronate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Pamidronate.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Pamidronate.Experimental, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pamidronate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pamidronate.Approved
OmeprazoleThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Pamidronate.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Pamidronate.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pamidronate.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pamidronate.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pamidronate.Approved, Vet Approved
PantoprazoleThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Pantoprazole.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Pamidronate.Approved
ParomomycinParomomycin may increase the hypocalcemic activities of Pamidronate.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Pamidronate.Investigational
PeruvosidePeruvoside may decrease the cardiotoxic activities of Pamidronate.Experimental
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pamidronate.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pamidronate.Approved, Investigational
PirarubicinPirarubicin may increase the hypocalcemic activities of Pamidronate.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Pamidronate.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pamidronate.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Pamidronate.Experimental
PlazomicinPlazomicin may increase the hypocalcemic activities of Pamidronate.Investigational
PlicamycinPlicamycin may increase the hypocalcemic activities of Pamidronate.Approved, Investigational, Withdrawn
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Pamidronate.Experimental, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Pamidronate.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Pamidronate.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Pamidronate.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Pamidronate.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Pamidronate.Experimental
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Pamidronate.Investigational
PuromycinPuromycin may increase the hypocalcemic activities of Pamidronate.Experimental
RabeprazoleThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Rabeprazole.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pamidronate.Approved, Experimental, Investigational
RibostamycinRibostamycin may increase the hypocalcemic activities of Pamidronate.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Pamidronate.Investigational, Withdrawn
SabarubicinSabarubicin may increase the hypocalcemic activities of Pamidronate.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Pamidronate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pamidronate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Pamidronate.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Pamidronate.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Pamidronate.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Pamidronate.Investigational
SisomicinSisomicin may increase the hypocalcemic activities of Pamidronate.Investigational
SP1049CSP1049C may increase the hypocalcemic activities of Pamidronate.Investigational
SpectinomycinSpectinomycin may increase the hypocalcemic activities of Pamidronate.Approved, Investigational, Vet Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Pamidronate.Investigational
StreptomycinStreptomycin may increase the hypocalcemic activities of Pamidronate.Approved, Vet Approved
StreptozocinStreptozocin may increase the hypocalcemic activities of Pamidronate.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pamidronate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Pamidronate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Pamidronate.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Pamidronate.Experimental
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Pamidronate.Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Pamidronate.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Pamidronate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Pamidronate.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Pamidronate.Approved
ThalidomideThalidomide may increase the nephrotoxic activities of Pamidronate.Approved, Investigational, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pamidronate.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Pamidronate.Investigational
TobramycinTobramycin may increase the hypocalcemic activities of Pamidronate.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pamidronate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pamidronate.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Pamidronate.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pamidronate.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Pamidronate.Experimental
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Pamidronate.Investigational
TromethamineThe serum concentration of Pamidronate can be decreased when it is combined with Tromethamine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Pamidronate.Investigational, Withdrawn
ValrubicinValrubicin may increase the hypocalcemic activities of Pamidronate.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pamidronate.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Pamidronate.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pamidronate.Withdrawn
Zoptarelin doxorubicinZoptarelin doxorubicin may increase the hypocalcemic activities of Pamidronate.Investigational
ZorubicinZorubicin may increase the hypocalcemic activities of Pamidronate.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Edward C. Shinal, "Method for preparation of disodium pamidronate." U.S. Patent US6268524, issued February, 1988.

US6268524
General References
  1. Zarychanski R, Elphee E, Walton P, Johnston J: Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol. 2006 Jan;81(1):73-5. [PubMed:16369966]
External Links
Human Metabolome Database
HMDB14427
KEGG Compound
C07395
PubChem Compound
4674
PubChem Substance
46504823
ChemSpider
4512
BindingDB
12581
ChEMBL
CHEMBL834
Therapeutic Targets Database
DAP001416
PharmGKB
PA450767
HET
210
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Pamidronate
ATC Codes
M05BA03 — Pamidronic acid
AHFS Codes
  • 92:24.00 — Bone Resorption Inhibitors
PDB Entries
2f89 / 3sdr / 4kpj / 4nkf / 4ogu / 5erm / 5ero
FDA label
Download (59.5 KB)
MSDS
Download (49.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentRefractory Multiple Myeloma / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentSAPHO Syndrome1
1Unknown StatusTreatmentArthroplasty / Mineral Density1
1Unknown StatusTreatmentLow Back Pain (LBP)1
1, 2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm / Pain1
1, 2CompletedTreatmentChronic Low Back Pain (CLBP)1
1, 2TerminatedTreatmentBone destruction1
2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentMultiple Myeloma (MM)2
2RecruitingPreventionBone destruction / Osteopenia1
2RecruitingTreatmentImmune System Disease / Musculoskeletal Disorders1
2TerminatedTreatmentBreast Cancer, Metastatic / Cancer treatment1
2Unknown StatusTreatmentBack Pain / Intervertebral Disc Degeneration / Low Back Pain (LBP) / Magnetic Resonance Imaging (MRI) / Modic I Discopathy1
3CompletedPreventionMultiple Myeloma (MM)1
3CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
3CompletedTreatmentOsteogenesis Imperfecta1
4CompletedNot AvailableCancer, Breast / Neoplasms Metastasis1
4CompletedTreatmentBone Diseases, Metabolic1
4CompletedTreatmentBone Loss1
4CompletedTreatmentCancer, Breast1
4CompletedTreatmentBone destruction / Osteogenesis Imperfecta / Paget's Disease of Bone1
4CompletedTreatmentOsteopenia / Renal Osteodystrophy1
4CompletedTreatmentSpondyloarthropathies1
4Not Yet RecruitingPreventionAnkylosing Spondylitis (AS)1
4RecruitingTreatmentCancer, Breast / Metastasis / Prostate Cancer1
4WithdrawnNot AvailableMetastatic Bone Disease / Tumors, Solid1
Not AvailableCompletedPreventionBone destruction / Cerebral Palsy (CP) / Osteogenesis Imperfecta / Osteopenia / Spina Bifida1
Not AvailableCompletedTreatmentTransplant Bone Disease1
Not AvailableTerminatedTreatmentFemoral Head Avascular Necrosis1
Not AvailableWithdrawnPreventionOssification, Heterotopic1

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
  • Aesgen inc
  • Akorn strides llc
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Cipla ltd
  • Generamedix inc
  • Hospira inc
  • Mn pharmaceuticals
  • Pharmaforce inc
  • Pliva lachema as
  • Sun pharma global inc
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous60 mg
Powder, for solutionIntravenous30 mg
Powder, for solutionIntravenous90 mg
LiquidIntravenous3 mg
InjectionIntravenous3 mg/mL
InjectionIntravenous9 mg/mL
Injection, powder, lyophilized, for solutionIntravenous3 mg/mL
Injection, powder, lyophilized, for solutionIntravenous6 mg/mL
Injection, powder, lyophilized, for solutionIntravenous9 mg/mL
Injection, solutionIntravenous3 mg/mL
Injection, solutionIntravenous6 mg/mL
Injection, solutionIntravenous9 mg/mL
SolutionIntravenous3 mg
SolutionIntravenous6 mg
SolutionIntravenous3.0 mg
SolutionIntravenous6.0 mg
SolutionIntravenous9.0 mg
Powder, for solutionIntravenous15 mg
SolutionIntravenous9 mg
Prices
Unit descriptionCostUnit
Aredia 90 mg vial839.59USD each
Pamidronate disod 90 mg vial755.64USD each
Aredia 90 mg/vial548.05USD vial
Aredia 30 mg vial279.86USD each
Pamidronate Disodium 90 mg/vial258.28USD vial
Pamidronate Disodium Omega 90 mg/vial258.28USD vial
Pms-Pamidronate 90 mg/vial258.28USD vial
Aredia 30 mg/vial182.69USD vial
Pamidronate Disodium 60 mg/vial129.14USD vial
Pamidronate disod 30 mg vial111.94USD each
Pamidronate Disodium 30 mg/vial86.09USD vial
Pamidronate Disodium Omega 30 mg/vial86.09USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP-4.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility15.8 mg/mLALOGPS
logP-1.4ALOGPS
logP-4.5ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)0.67ChemAxon
pKa (Strongest Basic)9.86ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area161.31 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity42.62 m3·mol-1ChemAxon
Polarizability17.34 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9635
Blood Brain Barrier+0.6175
Caco-2 permeable-0.6924
P-glycoprotein substrateNon-substrate0.6937
P-glycoprotein inhibitor INon-inhibitor0.937
P-glycoprotein inhibitor IINon-inhibitor0.9868
Renal organic cation transporterNon-inhibitor0.9254
CYP450 2C9 substrateNon-substrate0.8427
CYP450 2D6 substrateNon-substrate0.7949
CYP450 3A4 substrateNon-substrate0.6827
CYP450 1A2 substrateNon-inhibitor0.7892
CYP450 2C9 inhibitorNon-inhibitor0.9049
CYP450 2D6 inhibitorNon-inhibitor0.9336
CYP450 2C19 inhibitorNon-inhibitor0.9049
CYP450 3A4 inhibitorNon-inhibitor0.8539
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9924
Ames testNon AMES toxic0.6692
CarcinogenicityNon-carcinogens0.7877
BiodegradationReady biodegradable0.6385
Rat acute toxicity1.7722 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8231
hERG inhibition (predictor II)Non-inhibitor0.8926
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic phosphonic acids and derivatives
Sub Class
Bisphosphonates
Direct Parent
Bisphosphonates
Alternative Parents
Organic phosphonic acids / 1,3-aminoalcohols / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives
Substituents
Bisphosphonate / Organophosphonic acid / 1,3-aminoalcohol / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative / Primary amine / Organophosphorus compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Poly(a) rna binding
Specific Function
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids...
Gene Name
FDPS
Uniprot ID
P14324
Uniprot Name
Farnesyl pyrophosphate synthase
Molecular Weight
48275.03 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41. [PubMed:10620343]
  3. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [PubMed:11160603]
  4. Notarnicola M, Messa C, Cavallini A, Bifulco M, Tecce MF, Eletto D, Di Leo A, Montemurro S, Laezza C, Caruso MG: Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis. Oncology. 2004;67(5-6):351-8. [PubMed:15713990]
  5. Riebeling C, Forsea AM, Raisova M, Orfanos CE, Geilen CC: The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br J Cancer. 2002 Jul 29;87(3):366-71. [PubMed:12177810]
  6. Zhang PL, Lun M, Siegelmann-Danieli N, Blasick TM, Brown RE: Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy. Ann Clin Lab Sci. 2004 Summer;34(3):263-70. [PubMed:15487700]
Kind
Small molecule
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
References
  1. Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [PubMed:20209564]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34